Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 198

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus

Open access
Mina, Rina, von Scheven, Emily, Ardoin, Stacy P., Eberhard, B. Anne, Punaro, Marilynn, Ilowite, Norman, Hsu, Joyce, Klein‐gitelman, Marisa, Moorthy, L. Nandini, Muscal, Eyal, Radhakrishna, Suhas M., Wagner‐weiner, Linda, Adams, Matthew, Blier, Peter, Buckley, Lenore, Chalom, Elizabeth, Chédeville, Gaëlle, Eichenfield, Andrew, Fish, Natalya, Henrickson, Michael, Hersh, Aimee O., Hollister, Roger, Jones, Olcay, Jung, Lawrence, Levy, Deborah, Lopez‐Benitez, Jorge, McCurdy, Deborah, Miettunen, Paivi M., Quintero‐Del Rio, Ana I., Rothman, Deborah, Rullo, Ornella, Ruth, Natasha, Schanberg, Laura E., Silverman, Earl, Singer, Nora G., Soep, Jennifer, Syed, Reema, Vogler, Larry B., Yalcindag, Ali, Yildirim‐toruner, Cagri, Wallace, Carol A., Brunner, Hermine I., Carra SLE Subcommittee · 2012 · Arthritis Care & Research

Abstract

Objective: To formulate consensus treatment plans (CTPs) for induction therapy of newly diagnosed proliferative lupus nephritis (LN) in juvenile systemic lupus erythematosus (SLE). Methods: A structured consensus formation process was employed by the members of the Childhood Arthritis and Rheumatology Research Alliance after considering the existing medical evidence and current treatment approaches. Results: After an initial Delphi survey (response rate = 70%), a 2‐day consensus conference, and 2 followup Delphi surveys (response rates = 63–79%), consensus was achieved for a limited set of CTPs addressing the induction therapy of proliferative LN. These CTPs were developed for prototypical patients defined by eligibility characteristics, and included immunosuppressive therapy with either mycophenolic acid orally twice per day, or intravenous cyclophosphamide once per month at standardized dosages for 6 months. Additionally, the CTPs describe 3 options for standardized use of glucocorticoids, including a primarily oral, a mixed oral/intravenous, and a primarily intravenous regimen. There was consensus on measures of effectiveness and safety of the CTPs. The CTPs were well accepted by the pediatric rheumatology providers treating children with LN, and up to 300 children per year in North America are expected to be candidates for the treatment with the CTPs. Conclusion: CTPs for induction therapy of proliferative LN in juvenile SLE based on the available scientific evidence and pediatric rheumatology group experience have been developed. Consistent use of the CTPs may improve the prognosis of proliferative LN, and support the conduct of comparative effectiveness studies aimed at optimizing therapeutic strategies for proliferative LN in juvenile SLE.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/acr.21558

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 198

Metadata

Authors
Mina, R., von Scheven, E., Ardoin, S. P., Eberhard, B. A., Punaro, M., Ilowite, N., Hsu, J., Klein‐gitelman, M., Moorthy, L. N., Muscal, E., Radhakrishna, S. M., Wagner‐weiner, L., Adams, M., Blier, P., Buckley, L., Chalom, E., Chédeville, G., Eichenfield, A., Fish, N., Henrickson, M., Hersh, A. O., Hollister, R., Jones, O., Jung, L., Levy, D., Lopez‐Benitez, J., McCurdy, D., Miettunen, P. M., Quintero‐Del Rio, A. I., Rothman, D., Rullo, O., Ruth, N., Schanberg, L. E., Silverman, E., Singer, N. G., Soep, J., Syed, R., Vogler, L. B., Yalcindag, A., Yildirim‐toruner, C., Wallace, C. A., Brunner, H. I., & Subcommittee, C. S.
Venue
Arthritis Care & Research
Publisher
Wiley
Published
2012-02-28
Volume
64
Issue
3
Pages
375-383
ISSN
  • 0893-7524 (ISSN-L)
  • 2151-464X
  • 2151-4658
OpenAlex
W2098488998
Cited by
198
References
2
FWCI
6.66
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.